Otsuka Can Block Generic Abilify as Court Rejects Appeal
Published: Jan 15, 2013
The U.S. Supreme Court left intact a ruling that lets Otsuka Holdings Co. (4578)’s pharmaceutical unit block generic competition to its schizophrenia drug Abilify in the U.S. until April 2015. The justices today turned away an appeal by Canadian generic-drug maker Apotex Corp. The company challenged the patent for Abilify’s active ingredient, contending it would have been obvious to scientists based on known research. A U.S. appeals court rejected that argument. The drug generates sales of more than $5 billion a year, making it the fourth largest-selling drug in the U.S., Otsuka said, citing data from researcher IMS Health. New York-based Bristol-Myers Squibb Co. (BMY), which markets the drug with Otsuka, reported its share of Abilify sales was $2 billion in the first nine months of last year, or 15 percent of its revenue. Apotex said the active ingredient aripiprazole belongs to a class of compounds that have been known since the early 1980s and were covered by a patent that expired in 2005. The legal standard for deciding that question is too broad and “permits pharmaceutical companies to obtain or maintain patent monopoly rights over large portions of what belongs in the public domain,” Apotex argued in its high court appeal.